SAGE and related approaches for cancer target identification

Drug Discovery Today
Dale PorterK Polyak

Abstract

Comprehensive genetic, epigenetic and transcriptional analyses of normal and cancerous tissues and cells have yielded many candidate diagnostic, predictive, and prognostic markers and therapeutic targets in human cancer. This article provides a brief overview of SAGE and SAGE-like techniques, highlighting their utility and advantages relative to other genomic technologies for the discovery of drug targets. We also summarize the results of recent comprehensive profiling studies that utilize these methods to provide insights into mechanisms of tumor initiation and progression, to improve our molecular understanding of the tumor microenvironment and to reveal new targets and avenues for therapeutic interventions.

References

Aug 19, 2000·Science·B St CroixK W Kinzler
Jun 30, 2001·The New England Journal of Medicine·O I Olopade, T Grushko
Aug 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·I E KropK Polyak
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Nov 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·A BhattacharjeeM Meyerson
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Apr 5, 2002·Nature·Ina RheeBert Vogelstein
May 1, 2002·Nature Biotechnology·Saurabh SahaVictor E Velculescu
Jun 28, 2002·Cancer Cell·Dinesh SinghWilliam R Sellers
Sep 26, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jonathan R PollackPatrick O Brown
Dec 4, 2002·Proceedings of the National Academy of Sciences of the United States of America·Tian-Li WangVictor E Velculescu
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Dec 24, 2002·Seminars in Immunology·Fran Balkwill
Mar 1, 2003·Proceedings of the National Academy of Sciences of the United States of America·Ingrid HedenfalkJeffrey Trent
Jul 5, 2003·Cancer Cell·Yibin KangJoan Massagué
Nov 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·Joshua B RubinRosalind A Segal
Dec 10, 2003·Proceedings of the National Academy of Sciences of the United States of America·Toshiyuki ShirakiYoshihide Hayashizaki
Dec 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hideo MatsumuraRyohei Terauchi
Feb 6, 2004·Proceedings of the National Academy of Sciences of the United States of America·Byung Joon HwangPaul W Sternberg
Feb 19, 2004·Proceedings of the National Academy of Sciences of the United States of America·Tian-Li WangVictor E Velculescu
Jul 6, 2004·Nature Biotechnology·Tae-young RohKeji Zhao
Jul 21, 2004·Cancer Cell·Minna AllinenKornelia Polyak
Jul 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Chia-Lin WeiYijun Ruan
Aug 27, 2004·Nucleic Acids Research·Torstein TengsMatthew Meyerson
Sep 17, 2004·Nucleic Acids Research·Anna M HeidenblutStephan A Hahn
Nov 3, 2004·Cancer Research·Belinda S ParkerStephen L Madden
Dec 3, 2004·Cancer Research·Matthew C P SmithGary D Luker
Feb 17, 2005·Functional & Integrative Genomics·Adel F M IbrahimRobbie Waugh
Apr 6, 2005·Drug Discovery Today·Miroslava Cuperlovic-CulfRodney J Ouellette
May 28, 2005·Nature Genetics·Daniel Pinkel, Donna G Albertson
Jun 24, 2005·Nature Methods·Matthias Harbers, Piero Carninci
Jul 12, 2005·Nature Genetics·Min HuKornelia Polyak

❮ Previous
Next ❯

Citations

Apr 15, 2008·Molecular Diversity·Christopher Hulme, Yeon-Sun Lee
Dec 15, 2010·BMC Molecular Biology·Matthew J NesbittNansheng Chen
Sep 30, 2008·BioData Mining·Haiying WangFrancisco Azuaje
Jul 5, 2008·Drug Discovery Today·Robert L StrausbergYu-Hui Rogers
May 10, 2007·Nature Protocols·Min Hu, Kornelia Polyak
Jul 25, 2006·Nuclear Receptor Signaling·Luz E Tavera-MendozaJohn H White
May 3, 2018·Nucleic Acids Research·Adam J BogdanoveBarry L Stoddard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.